SCHEMBL802671

SCHEMBL802671

Cc1ccccc1-c1cc(Nc2n[nH]c3ccccc23)c(C)c(C)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FADS1 O60427 2/20 0.41
TRPA1 O75762 1/20 0.41
GRM4 Q14833 4/20 0.40
ADRA2A P08913 2/20 0.39
CYP1A2 P05177 1/20 0.37
BRD4 O60885 1/20 0.36
PIK3CD O00329 2/20 0.36
PIK3CA P42336 2/20 0.36
PIK3CB P42338 2/20 0.36
PIK3CG P48736 2/20 0.36
TNIK Q9UKE5 1/20 0.36
MTOR P42345 1/20 0.36
NPC1 O15118 1/20 0.36
ALDH1A1 P00352 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
AURKA O14965 1/20 0.36
ULK1 O75385 1/20 0.35
EGFR P00533 1/20 0.35
IDO1 P14902 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL802322 0.88 FADS1 (0.45) FADS1TRPA1GRM4ADRA2ANPC1
SCHEMBL802250 0.88 FADS1 (0.45) FADS1GRM4CYP1A2ULK1EGFR
SCHEMBL10267468 0.85 ACP1 (0.45) FADS1TRPA1GRM4CYP1A2BRD4
SCHEMBL802674 0.83 GSK3A (0.44) FADS1TRPA1GRM4ADRA2ACYP1A2
SCHEMBL802274 0.82 PIK3CA (0.42) FADS1TRPA1GRM4ADRA2APIK3CD
SCHEMBL802329 0.81 VCP (0.38) FADS1TRPA1GRM4ADRA2ACYP1A2
SCHEMBL801658 0.80 GRM4 (0.48) GRM4CYP1A2PIK3CAALDH1A1SMN1; SMN2
SCHEMBL802280 0.80 FADS1 (0.42) FADS1TRPA1GRM4ADRA2APIK3CD
SCHEMBL802326 0.80 FADS1 (0.48) FADS1TRPA1GRM4ADRA2ACYP1A2
SCHEMBL802027 0.78 FADS1 (0.46) FADS1TRPA1GRM4ADRA2ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633210-B2 Triazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-01-21 US disclosed
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS GSK3B, GSK3A, CDK19 FADS1 3442/4885TRPA1 4786/4885GRM4 3726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.